August 10, 2017
Opting for cheaper prescription drugs seems like an obvious way to cut health care costs. The assumption has led health plans to employ utilization management techniques with increasing frequency in recent years. And it’s given rise to a newer phenomenon known as “non-medical switching,” where health plans exclude a drug from coverage or increase patients’ out-of-pocket burden in hopes of persuading patients to take a less expensive drug.
August 1, 2017
People are living longer, healthier lives today with the help of advanced medicine. But innovative drugs can be expensive. Insurance…
July 17, 2017
Do coverage decisions aim to offer patients more treatment options – or drive patients to non-identical drugs based on cost alone?
June 9, 2017
EU regulators who want to encourage understanding and acceptance of biosimilar medicines might consider improving the drugs’ labels.
June 6, 2017
For chronic migraine patients, the only thing better than making a headache stop is preventing it altogether. And new research suggests that patients may soon have new options for doing just that.
May 16, 2017
One in every three new drugs triggers side effects discovered only after Food and Drug Administration approval, new data reveals. And that statistic begs a crucial question: How can we really ensure patients’ safety in an age of sophisticated medications and accelerated approval processes?
May 10, 2017
When should patients switch from one medicine to another for non-medical reasons? How can pharmacovigilance processes successfully monitor patients’ reactions to a medicine? And, perhaps most importantly, how do we ensure that patients are informed participants in decisions about their medication?
April 19, 2017
On April 6, 2017, the Institute for Patient Access convened the second annual National Policy and Advocacy Summit…
April 10, 2017
Physicians and patients are no longer asking if a biological medicine is the best choice, but – more likely – which biological medicine is the best choice. This opening thought from Alliance for Patient Access Chairman David Charles, MD, set the tone for the organization’s second annual National Policy and Advocacy Summit on Biologics and Biosimilars, held Thursday in Washington, DC.
April 4, 2017
First came biologics, then biosimilars. And soon, explains a newly released video from The Alliance for Patient Access, patients can expect interchangeable biosimilars.
